The invention is directed to isomeric mixtures of cyclosporine analogs that are structurally similar to cyclosporine A. The mixtures possess enhanced efficacy and reduced toxicity over the individual isomers and over naturally occurring and other presently known cyclosporines and cyclosporine derivatives. Embodiments of the present invention are directed toward cis and trans-isomers of cyclosporin A analogs referred to as ISA.sub.TX247, and derivatives thereof. Mixtures of ISA.sub.TX247 isomers exhibit a combination of enhanced potency and reduced toxicity over the naturally occurring and presently known cyclosporins. ISA.sub.TX247 isomers and alkylated, arylated, and deuterated derivatives are synthesized by stereoselective pathways where the particular conditions of a reaction determine the degree of stereoselectivity. The ratio of isomers in a mixture comprises greater than about 80 percent by weight of the E-isomer and less than about 20 percent by weight of the Z-isomer, based on the total weight of the mixture.

The present invention provides isolated stabilized EPO-derived peptides and their mimics that protect against tissue damage in subjects having diverse forms of neural and non-neural organ system injury, pharmaceutical compositions containing the isolated stabilized EPO-derived peptides, methods for treating symptoms of a disease, disorder or condition having an inflammatory or an autoimmune component in a subject in need thereof, and methods for downregulating immune mediator activity in a subject in need thereof.

Eph A receptor inhibitor peptides, and particularly Eph A4 receptor inhibitor peptides, are provided. The peptides comprise a sequence derived from the G-H loop of ephrin A4. Further, pharmaceutical compositions comprising said peptides and use thereof in treating, ameliorating or preventing diseases associated with memory formation are provided.

The present invention relates to compositions forming a low viscosity mixture of: a) at least one diacyl glycerol; b) at least one phosphatidyl choline; c) at least one oxygen containing organic solvent; d) at least one GnRH analog; Wherein the pre-formulation forms, or is capable of forming, at least one liquid crystalline phase structure upon contact with an aqueous fluid. The invention further relates to methods of treatment comprising administration of such compositions, pre-filled administration devices and kits containing the formulations.

Compositions and methods for treating melanoma are provided. Compositions include BRAF.sub.V600E-based peptides, alone or admixed with T helper peptides. Other compositions include nucleic acid sequences encoding the BRAF.sub.V600E-based peptides, alone or admixed with nucleic acid sequences T helper peptides. Dendritic cells pretreated with the BRAF.sub.V600E-based peptides, alone or admixed with T helper peptides, are also provided. These compositions are useful to treat melanoma, optionally co-administered with antibodies to checkpoint inhibitors or molecules that mimic the action of such antibodies.

Field of application: The invention relates to medicine and pharmacy and allows to obtain new pharmaceutical compositions based on polymyxin for the treatment of severe infectious diseases, but not possessing nephrotoxic properties in therapeutic doses. Technical result: New combined dosage forms based on the antibiotic polymyxin with low nephrotoxicity and high activity.

The present invention relates to an immunogen for use in preventing or treating familial frontotemporal dementia (FTD), amyotrophic lateral sclerosis (ALS) and/or amyotrophic lateral sclerosis-frontotemporal dementia (ALS-FTD) in patients with C9orf72 repeat expansion. The immunogen is comprising or consisting of a polypeptide consisting of dipeptide-repeats with a sequence selected from the group consisting of (Gly-Ala)a, (Gly-Pro)a, (Gly-Arg)a, (Pro-Ala)a and (Pro-Arg)a, wherein a is an integer of 4 to 25.

An activity-based nanosensor composition for detecting protease activity comprising a cleavable detectable substrate and methods of use are disclosed.

An activity-based nanosensor composition for detecting protease activity comprising a cleavable detectable substrate and methods of use are disclosed.

An isolated or a synthetic targeting peptide comprising an amino acid sequence that is at least 90% identical to SEQ ID NO: 8 is disclosed. The targeting peptide may be conjugated to a component selected from the group consisting of polymeric micelles, lipoprotein-based drug carriers, nanoparticle drug carriers, a chemotherapeutic agent, a micelle, a liposome, dendrimers, a polymer, a lipid, an oligonucleotide, a peptide, a polypeptide, a protein, a prostate cancer cell, a stem cell, and an imaging agent. Also disclosed are a kit for imaging and detecting the presence of prostate cancer cells in vivo or in vitro, and a composition for treating prostate cancer, inhibiting prostate cancer cell growth, inducing prostate cancer cell cytotoxicity, and/or increasing the survival rate in a prostate cancer patient.